Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: Classification of the severity of obstruction and the clinical severity of chronic obstructive pulmonary disease (COPD)

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques:

Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques:

Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: Pharmacological compounds used in the therapy of chronic obstructive pulmonary disease

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques:

Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic obstructive pulmonary disease (COPD)

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques: Biomarker Discovery

Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques:

Journal: Basic & Clinical Pharmacology & Toxicology

Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

doi: 10.1111/bcpt.12366

Figure Lengend Snippet: The principles of combining drugs used to treat chronic obstructive pulmonary disease (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful

Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

Techniques: Medications

Journal: International Journal of General Medicine

Article Title: Usefulness of inspiratory capacity measurement in COPD patients in the primary care setting

doi: 10.2147/ijgm.s4824

Figure Lengend Snippet: Figure 1 Study population. Total numbers with inclusion and exclusion criteria and nonresponse. Abbreviation: COPD, chronic obstructive pulmonary disease.

Article Snippet: correspondence: Antonio Martín Pfizer Spain, Avenida de Europa 20B, Parque empresarial La Moraleja, 28108 Alcobendas, Madrid, spain Tel +34 490 96 28 Fax +34 91 490 97 21 Email antonio.martin@pfizer.com Objective: To determine if inspiratory capacity (IC) assessment could be useful for chronic obstructive pulmonary disease (COPD) patient management in the primary care setting.

Techniques: